1338367-36-4

Upstream product

• 2084-13-1 3-carboxymethyl-benzoic acid 
• 52798-00-2 (3-cyano-phenyl)-acetic acid methyl ester 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 1878-67-7 3-Bromophenylacetic acid 
• 113496-14-3 methyl 3-carboxyphenyl acetate 

Downstream Products

• 627860-93-9 C₁₃H₁₅NO₃ 
• 1338367-33-1 (3-{[(4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}phenyl)amino]carbonyl}phenyl)acetic acid 
• 1338367-37-5 C₂₆H₂₆N₂O₅ 

Relevant academic research and scientific papers

Pyridineacetamide derivative serving as CDK inhibitor, and preparation method and application thereof

The invention belongs to the technical field of pyridineacetamide derivatives, and particularly relates to a pyridineacetamide derivative serving as a CDK inhibitor and a preparation method and application of the pyridine acetamide derivative. The pyridineacetamide derivative shows excellent CDK9/CDK7 enzyme inhibitory activity, and can be used for preparing drugs used for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors such as breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

Design and synthesis of new prostaglandin D2 receptor antagonists

To identify new cost-effective prostaglandin D2 (DP) receptor antagonists, a series of novel 3-benzoylaminophenylacetic acids were synthesized and biologically evaluated. Among those tested, some representative compounds were found to be orally

MORPHOLINYLMETHYLUREAS CCR-3 RECEPTOR ANTAGONISTS

Compounds of formula (I'): (I); wherein: R1 represents substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; X represents -(CRkaRkb)k-; Rka and Rkb are each independ